Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by carduon Apr 24, 2010 9:04am
670 Views
Post# 17027201

Proposed Options

Proposed OptionsShareholders should read the circular issued prior to the AGM on May 11. The Board is recommending that the number of options that can be issued to company officers be increased by 50%. From about 4 million to about 6 million. The present 4 million options have an average strike price of $4.72. All but 200,000 have been issued.

So it appears that "they" are not happy with a strike price that is probably lower than a lot of long suffering "ordinary" shareholders paid for their shares. They now want another 2 million at a strike price which will reflect the closing market price the day following the AGM. As we are 18 days from that date and the PPS is continuing it's downward spiral on low volume in the absence of any "substantial" news, one could speculate that the price of the options will be less that $3.

Correct me if I'm wrong, but is it not the function of management, among other things, to enhance ALL shareholders value in the company, not just their own. Or am I being naive! Ha,ha.
Bullboard Posts